Nanobiotix S.A. (LON:0QAV)
8.45
-0.09 (-1.08%)
At close: Sep 12, 2025
Nanobiotix Revenue
In the year 2024, Nanobiotix had annual revenue of -7.19M EUR, down -119.86%. Nanobiotix had revenue of -16.48M in the half year ending December 31, 2024, a decrease of -578.07%.
Revenue
-7.19M EUR
Revenue Growth
-119.86%
P/S Ratio
-55.75
Revenue / Employee
-66.57K EUR
Employees
108
Market Cap
331.51M GBP
Revenue Chart
* This company reports financials in EUR.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | -7.19M | -43.40M | -119.86% |
Dec 31, 2023 | 36.21M | 31.43M | 658.12% |
Dec 31, 2022 | 4.78M | 2.13M | 80.43% |
Dec 31, 2021 | 2.65M | 322.00K | 13.85% |
Dec 31, 2020 | 2.33M | -216.00K | -8.50% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 41.24B |
GSK plc | 31.63B |
Haleon | 11.02B |
Smith & Nephew | 4.33B |
ConvaTec Group | 1.72B |
Hikma Pharmaceuticals | 2.35B |
HUTCHMED (China) | 439.54M |
Genus | 672.80M |
Nanobiotix News
- 13 days ago - Nanobiotix to Participate in the H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire
- 2 months ago - NANOBIOTIX Announces Regulatory Harmonization and New Composition of Matter Patent Filed for JNJ-1900 (NBTXR3) - GlobeNewsWire
- 3 months ago - NANOBIOTIX to Participate in the Jefferies Global Healthcare Investor Conference - GlobeNewsWire
- 4 months ago - Nanobiotix Provides First Quarter 2025 Operational and Financial Update - GlobeNewsWire
- 4 months ago - Nanobiotix to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ - GlobeNewsWire
- 4 months ago - Nanobiotix Announces Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in ... - GuruFocus
- 4 months ago - Nanobiotix Announces Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer - GlobeNewsWire
- 4 months ago - Nanobiotix Announces Presentation of Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer Followed by a Conference Call - GlobeNewsWire